Beilstein Arch. 2020, 202024. https://doi.org/10.3762/bxiv.2020.24.v1
Published 06 Mar 2020
Doxorubicin is a widely used antineoplastic agent for the treatment of various types of cancer. However, it is also a highly toxic drug because it induces the generation of oxidative stress. Thus, the use of antioxidant molecules has been considered to reduce the toxicity of doxorubicin. In this report, we investigated whether the use of chitosan-glutathione (CH-GSH) nanoparticles could reduce cell damage induced by doxorubicin on breast cancer cells. CH-GSH NPs were characterized in size, Zeta potential, concentration, and shape. When breast cancer cells were treated with CH-GSH nanoparticles, these were localized in the cellular cytoplasm. Combined exposure of doxorubicin and nanoparticle increased intracellular GSH levels while decreasing reactive oxygen species and malondialdehyde levels. The antioxidant enzyme activity was also decreased. Together our data suggest that the use of CH-GSH nanoparticles can reduce the oxidative stress induced by doxorubicin on breast cancer cells.
Keywords: Doxorubicin; oxidative stress; nanoparticles; glutathione; chitosan
When a peer-reviewed version of this preprint is available, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:
López-Barrera, L. D.; Díaz-Torres, R.; Martínez-Rosas, J. R.; Salazar Martínez, A. M.; Rosales, C.; Ramirez-Noguera, P. Beilstein Arch. 2020, 202024. doi:10.3762/bxiv.2020.24.v1
|Download RIS (Reference Manager)||Download BIB (BIBTEX)|
© 2020 López-Barrera et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited.
The license is subject to the Beilstein Archives terms and conditions: (https://www.beilstein-archives.org/xiv/terms)